Core Insights - Science 37 and Catalent have formed a strategic partnership to enhance the delivery of investigational medicinal products (IMPs) directly to patients' homes for clinical research [1][2] - The collaboration aims to remove geographic barriers, allowing for more diverse patient populations and faster enrollment in clinical trials [3] Company Overview - Science 37 focuses on expanding patient access to clinical trials, leading to quicker approvals and improved health outcomes [8] - Catalent is a global leader in contract development and manufacturing, dedicated to supporting product development and supply for pharma, biotech, and consumer health sectors [6] Partnership Details - Catalent provides logistics services for Science 37's Direct-to-Patient Clinical Trial Site model, ensuring efficient and secure delivery of study medications [2] - The partnership has successfully enrolled nearly 1,700 patients across 17 studies, with an average of 26% of the total study population enrolled at a single Direct-to-Patient Site [3] Operational Benefits - The integrated solution offers sponsors a streamlined clinical trial site under a single contract and budget, improving enrollment speed and retention rates [4] - The partnership has delivered over 6,400 shipments to study participants, demonstrating its operational efficiency [3]